Comera Life Sciences Statistics
Share Statistics
Comera Life Sciences has 30.74M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 30.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.37M |
| Failed to Deliver (FTD) Shares | 285 |
| FTD / Avg. Volume | 3.43% |
Short Selling Information
The latest short interest is 281.55K, so 0.92% of the outstanding shares have been sold short.
| Short Interest | 281.55K |
| Short % of Shares Out | 0.92% |
| Short % of Float | 6.44% |
| Short Ratio (days to cover) | 0.84 |
Valuation Ratios
The PE ratio is -0.71 and the forward PE ratio is null.
| PE Ratio | -0.71 |
| Forward PE | null |
| PS Ratio | 20.31 |
| Forward PS | null |
| PB Ratio | -2.06 |
| P/FCF Ratio | -1.31 |
| PEG Ratio | n/a |
Enterprise Valuation
Comera Life Sciences Inc. has an Enterprise Value (EV) of 13.19M.
| EV / Earnings | -0.73 |
| EV / Sales | 20.83 |
| EV / EBITDA | -0.74 |
| EV / EBIT | -1.1 |
| EV / FCF | -1.35 |
Financial Position
The company has a current ratio of 0.61, with a Debt / Equity ratio of -0.07.
| Current Ratio | 0.61 |
| Quick Ratio | 0.61 |
| Debt / Equity | -0.07 |
| Total Debt / Capitalization | -7.87 |
| Cash Flow / Debt | -21.45 |
| Interest Coverage | -587.02 |
Financial Efficiency
Return on equity (ROE) is 2.88% and return on capital (ROIC) is 218.75%.
| Return on Equity (ROE) | 2.88% |
| Return on Assets (ROA) | -4.83% |
| Return on Capital (ROIC) | 218.75% |
| Revenue Per Employee | 52.76K |
| Profits Per Employee | -1.50M |
| Employee Count | 12 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -20.43, so Comera Life Sciences 's price volatility has been lower than the market average.
| Beta | -20.43 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 35.04 |
| Average Volume (20 Days) | 8.30K |
Income Statement
In the last 12 months, Comera Life Sciences had revenue of 633.10K and earned -18.00M in profits. Earnings per share was -1.76.
| Revenue | 633.10K |
| Gross Profit | 422.71K |
| Operating Income | -11.97M |
| Net Income | -18.00M |
| EBITDA | -17.89M |
| EBIT | -11.97M |
| Earnings Per Share (EPS) | -1.76 |
Balance Sheet
The company has 446.61K in cash and 775.05K in debt, giving a net cash position of -328.44K.
| Cash & Cash Equivalents | 446.61K |
| Total Debt | 775.05K |
| Net Cash | -328.44K |
| Retained Earnings | -34.90M |
| Total Assets | 3.07M |
| Working Capital | -301.92K |
Cash Flow
In the last 12 months, operating cash flow was -9.77M and capital expenditures -28.61K, giving a free cash flow of -9.80M.
| Operating Cash Flow | -9.77M |
| Capital Expenditures | -28.61K |
| Free Cash Flow | -9.80M |
| FCF Per Share | -0.94 |
Margins
Gross margin is 6.68K%, with operating and profit margins of -189.07K% and -284.38K%.
| Gross Margin | 6.68K% |
| Operating Margin | -189.07K% |
| Pretax Margin | -284.38K% |
| Profit Margin | -284.38K% |
| EBITDA Margin | -2.83K% |
| EBIT Margin | -1.89K% |
| FCF Margin | -1.55K% |
Dividends & Yields
CMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | -159407.56% |
Analyst Forecast
Currently there are no analyst rating for CMRA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -28.11 |
| Piotroski F-Score | 2 |